Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …

Targeted therapy has stepped into the perioperative treatment arena and launched a radical
revolution in the treatment of early-stage oncogene-driven non-small-cell lung cancer …

Simple Summary Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of
all lung cancers, and the postoperative survival of early-stage NSCLC patients remains …

The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSCLC) is
rapidly evolving. As already happened for the advanced disease, also early stages have …

Objectives The molecular profiles and prognosis of anaplastic lymphoma kinase (ALK)
fusion and resectable non-small cell lung cancer (NSCLC) remain unclear. This study aimed …

Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Background Despite surgical resection, early lung adenocarcinoma has a recurrence rate of
20–50%. No clear predictive markers for recurrence of early lung adenocarcinoma are …

Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the
treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 …

Introduction Survival rates for early-stage non-small cell lung cancer (NSCLC) remain poor
despite the decade-long established standard of surgical resection and systemic adjuvant …

In this study, we aim to investigate the therapeutic effect and safety of ALK inhibitor in ALK-
positive lung cancer patients. 59 patients with ALK-positive lung cancer from August 2013 to …